Effective therapy for heart failure with preserved ejection fraction
January 7, 2022
Dr. Anderson Clinical question: What effect do sodium-glucose cotransporter 2 (SGLT2) inhibitors have on outcomes in adults with heart failure with preserved ejection fraction...
New data on rare myocarditis after COVID-19 vaccination
December 8, 2021
Most adolescents and young adults recover quickly from the rare complication of myocarditis following mRNA COVID-19 vaccination, a new study shows.
SGLT2 inhibitor use tied to fewer atrial arrhythmias
December 2, 2021
A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.
Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved
November 19, 2021
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.
Empagliflozin a winner in challenging arena of stabilized acute HF
November 19, 2021
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.
EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients
November 17, 2021
A landmark trial proved empagliflozin’s efficacy in HFpEF, but many patients had “moderately reduced” EFs. The findings hold up even without them.
EHRs have no impact on inpatient heart failure clinical choices or outcomes
November 15, 2021
Relative to usual care, prognostic information at the bedside provided no advantage for heart failure care.
BP Track: Blood pressure control rates dropped during pandemic
November 14, 2021
Data culled from 24 health systems showed lower rates of blood pressure control during the COVID-19 pandemic.
New reports help nail down myocarditis risk with COVID-19 vaccine
October 11, 2021
Myocarditis linked to the two mRNA SARS-CoV-2 vaccines is rare, usually mild and self-limited, and a lot less likely than the usually more severe cases seen in COVID-19.
Heart failure hospitalization risk lower with SGLT2 inhibitors than GLP-1 RAs
September 27, 2021
SGLT2 inhibitor versus GLP-1 RA use was associated with a significantly lower rate of hospitalization for heart failure in people with diabetes.